Sarepta Therapeutics (SRPT) PT Lowered to $75 at Needham & Company; 'FY17 Guidance Significantly Below Expectations'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Instinet Starts Sarepta Therapeutics (SRPT) at Buy, $84 PT
March 1, 2017 4:24 PM ESTInstinet initiates coverage on Sarepta Therapeutics (NASDAQ: SRPT) with a Buy rating and a price target of $84.00.
Analyst Christopher Marai commented, "We are initiating coverage on Sarepta Therapeutics (SRPT) with a Buy rating and $84 target price. We recommend owning SRPT shares, expecting significant... More
Sarepta Therapeutics (SRPT) Sees Strong Red-to-Green Reversal
March 1, 2017 11:17 AM ESTSarepta Therapeutics (NASDAQ: SRPT) reverses large after-hours losses and goes positive as CMS update adds pass-thru drug code C9484 or Eteplirsen. LINK
Shares are up 1.4%.
... More
